**Renishaw plc** **Tel** +44 (0) 1453 524524

 **Fax** +44 (0) 1453 524901

New Mills, Wotton-under-Edge, **Email** uk@renishaw.com

Gloucestershire, GL12 8JR

United Kingdom **www.renishaw.com**

**News from Renishaw**

*March 2017 – for immediate release Further information: Chris Pockett, +44 1453 524133*

**Clinical study authorised in Sweden for the investigation of CDNF and Renishaw drug delivery system in Parkinson’s patients**

The Medicines Agency of Sweden, MPA, has authorised Herantis Pharma Plc and Renishaw plc’s randomised, placebo-controlled Phase 1-2 clinical study, for the investigation of Cerebral Dopamine Neurotrophic Factor (CDNF) and Renishaw’s chronic drug delivery system, in Parkinson’s patients.

The first study site to start patient recruitment will be the Karolinska University Hospital in Stockholm, Sweden. Two other university hospitals are planned to join the study later.  The clinical study intends to recruit a total of 18 patients with Parkinson’s disease.

Paul Skinner, General Manager for Renishaw’s Neurological Products Division, said, “This is an important step forward in the use of the Renishaw drug delivery system, and in gathering clinical data for the delivery of therapeutics across the blood-brain-barrier.”

Parkinson’s is a neurodegenerative disease, caused by the break-down of dopamine producing neurons in the brain. Symptoms include involuntary shaking, stiffness of muscles and slowing down of movement, which can be extremely debilitating. In addition, patients can suffer associated non-motor symptoms such as difficulty sleeping, memory loss, anxiety and depression. Whilst these symptoms can initially be managed with medication, there is currently no treatment available that effectively prevents disease progression, or that treats the motor and non-motor symptoms together.

CDNF aims to relieve the symptoms of Parkinson’s by protecting dopaminergic neurons and restoring their functionality. However, due to the size of the molecule it will not cross the blood brain barrier and therefore needs to be delivered directly into the brain. The clinical study has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement number 732386.

**About Renishaw**

Renishaw is one of the world's leading engineering and scientific technology companies, with expertise in precision measurement and healthcare. The company supplies products and services used in applications as diverse as jet engine and wind turbine manufacture, through to dentistry and brain surgery. It is also a world leader in the field of additive manufacturing (also referred to as 3D printing), where it designs and makes industrial machines which ‘print' parts from metal powder.

The Renishaw Group currently has more than 70 offices in 35 countries, with over 4,000 employees, of which 2,800 people are employed within the UK. The majority of the company's R&D and manufacturing is carried out in the UK and for the year ended June 2016 Renishaw achieved sales of £436.6 million of which 95% was due to exports. The company's largest markets are China, USA, Germany and Japan.

The Company’s success has been recognised with numerous international awards, including eighteen Queen’s Awards recognising achievements in technology, export and innovation.

**-ENDS-**